Annelise Bennaceur holds a Doctor of Medicine and Doctor of Sciences degrees. She is a Professor of Hematology at the Faculty of Medicine at Paris Saclay University. She serves as the head of the Inserm U935 unit and ESteamParis Sud Stem Cell platform at the university. Additionally, she acts as the director of 'INGESTEM,' a National Infrastructure program under the "Investissement d'Avenir" initiative. This program is dedicated to industrial pluripotent stem cell development for innovative cancer therapies and engineered tissue for regenerative medicine. Her expertise includes anti-tumor immunotherapy from her time at the Cancer Center of Gustave-Roussy Institut. She possesses international proficiency in induced pluripotent stem cells (iPSCs) and cell therapy. She is renowned in France as a pioneer in iPSCs and the derivation of the first embryonic stem cell lines. Annelise Bennaceur participated in revising the bioethics law and served as an expert member of the commission for clinical trials in cell therapy at the AFSSAPS. She holds membership in steering committees such as Medicen, DAS Biomaterials, and Regenerative Medicine, and is an expert member of scientific commissions on PSCs. Furthermore, she is a part of the international consortium GAiT, dedicated to the clinical use of PSCs. Annelise Bennaceur is an Officer of the Legion of Honor, recognized by the Order of Merit and the Order of Academic Palms.